Catalogo Articoli (Spogli Riviste)

OPAC HELP

Titolo:
INTRAVITREAL INJECTION OF OCTREOTIDE ACETATE
Autore:
ROBERTSON JE; WESTRA I; WOLTERING EA; WINTHROP KL; BARRIE R; ODORISIO TM; HOLMES D;
Indirizzi:
OREGON HLTH SCI UNIV,CASEY EYE INST,3375 SW TERWILLIGER BLVD PORTLANDOR 97201
Titolo Testata:
Journal of ocular pharmacology and therapeutics
fascicolo: 2, volume: 13, anno: 1997,
pagine: 171 - 177
SICI:
1080-7683(1997)13:2<171:IIOOA>2.0.ZU;2-F
Fonte:
ISI
Lingua:
ENG
Soggetto:
SOMATOSTATIN ANALOGS; GROWTH; ANGIOGENESIS; RETINOPATHY; INHIBITION;
Tipo documento:
Article
Natura:
Periodico
Settore Disciplinare:
Science Citation Index Expanded
Science Citation Index Expanded
Citazioni:
19
Recensione:
Indirizzi per estratti:
Citazione:
J.E. Robertson et al., "INTRAVITREAL INJECTION OF OCTREOTIDE ACETATE", Journal of ocular pharmacology and therapeutics, 13(2), 1997, pp. 171-177

Abstract

This study was conducted to determine the feasibility of injecting the somatostatin analogue, octreotide acetate (OA), into the vitreous cavity. Previous work suggests that octreotide effectively inhibits angiogenesis in vitro, thus its use in vivo may slow the progression of proliferative eye disease. Fifty micrograms of aqueous OA in 50 mu l aqueous solution was injected into the mid-vitreous of kitten eyes (n=6),and OA levels were monitored over 4 days. A long-acting release form of octreotide (OA-LAR) was also injected into the mid-vitreous of rabbit eyes at doses of 0.36 (n=16), 1.1 (n=1), 2.1 (n=1), 4.05 (n=1), 8.2(n=1), and 36 mg (n=3) in solution; and octreotide concentrations were measured at various time points over 42 days. OA concentrations weredetermined by a highly specific radioimmunoassay. Aqueous octreotide was eliminated rapidly (t1/2=16 hours) from the vitreous of the kitteneye, with only negligible amounts recoverable 4 days post-injection. In the long-acting form, OA in the rabbit eye reached peak levels at 28 days. By 42 days, OA levels had declined to the 14-day level. Doses of OA-LAR of 1.1 mg or less produced no gross evidence of clinical toxicity and elicited no grossly visible ocular side effects. Doses greater than 1.1 mg produced significant toxicity, including cataracts and rubeosis. The 28-day peak release for long-acting OA implies that monthly intravitreal injections could provide continual high levels of OA. Intravitreal injection of long-acting OA provides sustained, high concentrations of drug, and deserves further study as a potential treatment of proliferative eye diseases.

ASDD Area Sistemi Dipartimentali e Documentali, Università di Bologna, Catalogo delle riviste ed altri periodici
Documento generato il 29/09/20 alle ore 00:18:02